Go Pro

Jupiter Topco LLC Takes $17.71 Million Position in Kardigan, Inc. $KARD

Key Points

  • Jupiter Topco LLC acquired 749,703 shares of Kardigan, valued at approximately $17.71 million, giving it a roughly 0.80% stake. Legal & General Group also established a smaller position worth about $119,000.
  • Analyst sentiment is broadly positive, with four Buy ratings and one Hold rating and a consensus price target of $42.25; individual targets range from $37 to $46. Wall Street Zen was a notable exception, downgrading the stock to Sell.
  • Kardigan shares opened at $20.02 after declining 3.8%, while the clinical-stage therapeutics company reported a quarterly loss of $4.61 per share. Two directors separately purchased 1.25 million shares each at $16 per share.
  • MarketBeat previews the top five stocks to own by October 1st.

Jupiter Topco LLC acquired a new position in Kardigan, Inc. (NASDAQ:KARD - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 749,703 shares of the company's stock, valued at approximately $17,715,000. Jupiter Topco LLC owned about 0.80% of Kardigan at the end of the most recent reporting period.

Separately, Legal & General Group Plc acquired a new stake in Kardigan during the second quarter valued at approximately $119,000.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Leerink Partners began coverage on shares of Kardigan in a research report on Monday, July 13th. They issued an "outperform" rating and a $37.00 price target on the stock. Jefferies Financial Group assumed coverage on Kardigan in a research report on Monday, July 13th. They set a "buy" rating and a $40.00 price objective for the company. Wall Street Zen lowered Kardigan from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. TD Cowen started coverage on Kardigan in a report on Monday, July 13th. They issued a "buy" rating and a $46.00 target price on the stock. Finally, Zacks Research raised Kardigan to a "hold" rating in a research report on Wednesday, July 15th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $42.25.

Get Our Latest Research Report on KARD

Kardigan Stock Down 3.8%

Shares of KARD opened at $20.02 on Friday. The stock has a 50-day moving average price of $21.88. Kardigan, Inc. has a one year low of $16.25 and a one year high of $27.00.

Kardigan (NASDAQ:KARD - Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($4.61) earnings per share (EPS) for the quarter. As a group, analysts anticipate that Kardigan, Inc. will post -5.14 earnings per share for the current fiscal year.

Insider Activity at Kardigan

In other news, Director Arch Venture Partners Xiii, Ll acquired 1,250,000 shares of the stock in a transaction on Monday, June 22nd. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $20,000,000.00. Following the transaction, the director owned 15,042,035 shares in the company, valued at approximately $240,672,560. This trade represents a 9.06% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Paul L. Berns bought 1,250,000 shares of the business's stock in a transaction on Monday, June 22nd. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $20,000,000.00. Following the completion of the purchase, the director owned 15,042,035 shares in the company, valued at approximately $240,672,560. This trade represents a 9.06% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Kardigan Profile

(Free Report)

Kardigan Inc is a clinical-stage precision therapeutics company developing medicines which target the root cause of specific cardiovascular diseases. Kardigan Inc is based in South San Francisco, California.

Further Reading

Want to see what other hedge funds are holding KARD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kardigan, Inc. (NASDAQ:KARD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Kardigan Right Now?

Before you consider Kardigan, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kardigan wasn't on the list.

While Kardigan currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own - Fall 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines